Pliant shares spike on exploratory study results of lead drug in chronic liver disease

Lei Lei Wu

News Reporter

Pliant Therapeutics shared early-stage biomarker and imaging results, suggesting that patients with a chronic liver disease who received its drug had improved liver function compared …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pliant shares spike on exploratory study results of lead drug in chronic liver disease

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

BridgeBio’s heart disease drug Attruby sails past prescription estimates

How Keymed steered the China-to-US NewCo model in biotech

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pli­ant shares spike on ex­plorato­ry study re­sults of lead drug in chron­ic liv­er dis­ease

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pliant shares spike on exploratory study results of lead drug in chronic liver disease